Oral Thalidomide and Tegafur-uracil to Decrease Hepatocellular Carcinoma Recurrence

Clinical trial NCT02447679 · COMPLETED

Trial details

NCT number: NCT02447679
Sponsor: Chang Gung Memorial Hospital
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Adult Hepatocellular Carcinoma Recurrent Hepatocellular Carcinoma Adverse Reaction to Drug Vascular Endothelial Growth Factor Overexpression

Start date: 2010-08-01
Primary completion: 2017-01-31
Enrollment: 40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.